Comparison Overview

The Art File | Award-Winning Art Publisher

VS

The Center for Biosimilars

The Art File | Award-Winning Art Publisher

Union Chambers, Nottingham, undefined, NG12GB, GB
Last Update: 2025-11-27
View Profile
Between 750 and 799
http://www.theartfile.com

Founded in 1997, The Art File has established itself as a leading independent publisher of greeting cards, wrap, stationery, and gifts. Today our award-winning cards are sold worldwide through a broad band of design-inspired retailers, which include leading high street names and a vast array of independent stores. Many of our collections are created by our talented in-house design team, along with highly skilled freelance designers. Some of our popular licensed collections include Sara Miller London, English Heritage, Robert Reader and Kate Heiss. This combined resource allows us to refresh our collections and stay ahead of developing trends and contemporary fashion. Sustainability is a key focus for every area of our business. All our greeting cards, gift bags, and gift wrap board is sourced from sustainable sources, whilst all of our cards are printed in the UK. Our cards are offered plastic-free as standard and our boxed cards come in recyclable cardboard. In 2024 we were thrilled to partner with Ecologi and have since helped to plant thousands of trees around the world.

NAICS: 511
NAICS Definition:
Employees: 27
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

The Center for Biosimilars

undefined, Cranbury, NJ, undefined, undefined
Last Update: 2025-11-26
Between 700 and 749
http://www.centerforbiosimilars.com

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

NAICS: 511
NAICS Definition:
Employees: 2
Subsidiaries: 57
12-month incidents
0
Known data breaches
1
Attack type number
2

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/the-art-file-limited.jpeg
The Art File | Award-Winning Art Publisher
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/thecenterforbiosimilars.jpeg
The Center for Biosimilars
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
The Art File | Award-Winning Art Publisher
100%
Compliance Rate
0/4 Standards Verified
The Center for Biosimilars
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for The Art File | Award-Winning Art Publisher in 2025.

Incidents vs Book and Periodical Publishing Industry Average (This Year)

No incidents recorded for The Center for Biosimilars in 2025.

Incident History — The Art File | Award-Winning Art Publisher (X = Date, Y = Severity)

The Art File | Award-Winning Art Publisher cyber incidents detection timeline including parent company and subsidiaries

Incident History — The Center for Biosimilars (X = Date, Y = Severity)

The Center for Biosimilars cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/the-art-file-limited.jpeg
The Art File | Award-Winning Art Publisher
Incidents

No Incident

https://images.rankiteo.com/companyimages/thecenterforbiosimilars.jpeg
The Center for Biosimilars
Incidents

Date Detected: 08/2022
Type:Cyber Attack
Blog: Blog

Date Detected: 5/2018
Type:Breach
Attack Vector: Unauthorized Access
Blog: Blog

FAQ

The Art File | Award-Winning Art Publisher company demonstrates a stronger AI Cybersecurity Score compared to The Center for Biosimilars company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

The Center for Biosimilars company has historically faced a number of disclosed cyber incidents, whereas The Art File | Award-Winning Art Publisher company has not reported any.

In the current year, The Center for Biosimilars company and The Art File | Award-Winning Art Publisher company have not reported any cyber incidents.

Neither The Center for Biosimilars company nor The Art File | Award-Winning Art Publisher company has reported experiencing a ransomware attack publicly.

The Center for Biosimilars company has disclosed at least one data breach, while The Art File | Award-Winning Art Publisher company has not reported such incidents publicly.

The Center for Biosimilars company has reported targeted cyberattacks, while The Art File | Award-Winning Art Publisher company has not reported such incidents publicly.

Neither The Art File | Award-Winning Art Publisher company nor The Center for Biosimilars company has reported experiencing or disclosing vulnerabilities publicly.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds any compliance certifications.

Neither company holds any compliance certifications.

The Center for Biosimilars company has more subsidiaries worldwide compared to The Art File | Award-Winning Art Publisher company.

The Art File | Award-Winning Art Publisher company employs more people globally than The Center for Biosimilars company, reflecting its scale as a Book and Periodical Publishing.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds SOC 2 Type 1 certification.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds SOC 2 Type 2 certification.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds ISO 27001 certification.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds PCI DSS certification.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds HIPAA certification.

Neither The Art File | Award-Winning Art Publisher nor The Center for Biosimilars holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

ThingsBoard in versions prior to v4.2.1 allows an authenticated user to upload malicious SVG images via the "Image Gallery", leading to a Stored Cross-Site Scripting (XSS) vulnerability. The exploit can be triggered when any user accesses the public API endpoint of the malicious SVG images, or if the malicious images are embedded in an `iframe` element, during a widget creation, deployed to any page of the platform (e.g., dashboards), and accessed during normal operations. The vulnerability resides in the `ImageController`, which fails to restrict the execution of JavaScript code when an image is loaded by the user's browser. This vulnerability can lead to the execution of malicious code in the context of other users' sessions, potentially compromising their accounts and allowing unauthorized actions.

Published
Date
2025-11-27
Updated
Date
2025-11-27
Risk Information
cvss4
Base: 6.2
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:N/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to to verify that the token used during the code exchange originates from the same authentication flow, which allows an authenticated user to perform account takeover via a specially crafted email address used when switching authentication methods and sending a request to the /users/login/sso/code-exchange endpoint. The vulnerability requires ExperimentalEnableAuthenticationTransfer to be enabled (default: enabled) and RequireEmailVerification to be disabled (default: disabled).

Published
Date
2025-11-27
Updated
Date
2025-11-27
Risk Information
cvss3
Base: 9.9
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H
References
Description

Mattermost versions 11.0.x <= 11.0.2, 10.12.x <= 10.12.1, 10.11.x <= 10.11.4, 10.5.x <= 10.5.12 fail to sanitize team email addresses to be visible only to Team Admins, which allows any authenticated user to view team email addresses via the GET /api/v4/channels/{channel_id}/common_teams endpoint

Published
Date
2025-11-27
Updated
Date
2025-11-27
Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
References
Description

Exposure of email service credentials to users without administrative rights in Devolutions Server.This issue affects Devolutions Server: before 2025.2.21, before 2025.3.9.

Published
Date
2025-11-27
Updated
Date
2025-11-27
References
Description

Exposure of credentials in unintended requests in Devolutions Server.This issue affects Server: through 2025.2.20, through 2025.3.8.

Published
Date
2025-11-27
Updated
Date
2025-11-27
References